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The public reporting of patient outcomes is crucial for quality improvement and informing patient 
choice. However, outcome reporting in radiotherapy, despite being a major component of cancer 
control and cure, remains extremely limited internationally. Public reporting encounters a number of 
challenges: difficulties in defining meaningful measures of treatment quality, limitations in data 
infrastructure, and fragmented health insurance schemes. The National Prostate Cancer Audit (NPCA) 
carried out in the England and Wales National Health Service (NHS), demonstrates that it is feasible to 
develop outcome indicators for radiotherapy treatment including those using patient reported 
outcomes (PROs). This national programme provides a transparent mechanism for comparing 
performance of all NHS providers, with results accessible to patients, providers and policymakers. 
Using the NPCA as a case study we discuss the development of a radiotherapy outcomes reporting 
programme, its impact and future potential, and the challenges and opportunities to develop this 





The National Prostate Cancer Audit was initiated in April 2013 and set out to assess the structure, 
organisation and availability of prostate cancer services in England and Wales as well as to 
prospectively collect information on processes and outcomes of care for all men newly diagnosed with 
prostate cancer.1 In February 2019, as part of this remit, the NPCA established the first national 
radiotherapy outcomes reporting programme, which included all men receiving radical radiotherapy 
for prostate cancer in the National Health Service (NHS) in England and Wales.2 The results are 
published in the public domain in order to support greater transparency and quality improvement. 
This article discusses the background to public reporting of patient outcomes, the development of the 
NPCA’s reporting programme for prostate cancer, its impact, and the challenges and opportunities for 
broadening radiotherapy outcome reporting to other tumour types and health systems.  
Within cancer care there continues to be a focus on access to advanced and novel technologies with 
the aim of improving functional and survival outcomes for patients.3 However, it is widely 
acknowledged that irrespective of the perceived benefits of the technology, significant variations in 
the quality of care may exist. Reasons include differences in the skill of the physicians or teams that 
deliver the treatment, the clinical care pathway adopted and the infrastructure of the hospital with 
respect to facilities, human resources, and organisational structure.4 
As a result, many health systems publish indicators of the performance of hospitals and health care 
professionals in the public domain to provide transparency on differences in the quality of care that 
exist within that health system. This enables comparisons of performance over time, between 
hospitals and professionals and against pre-existing standards of care that have been defined from 
clinical trials and national consensus statements by professional bodies.5,6 It also provides a 
mechanism for informing value-based health care initiatives, which seek to define efficient and cost-
effective practices of care.7 
Currently four broad types of measures predominate8: outcomes measures (e.g. complications, post-
treatment function, quality of life, cancer-specific and overall survival); process measures (e.g. waiting 
times, procedure volume, length of stay); structural measures (e.g. availability of specific technologies 
or services); and measures of patient experience and satisfaction. 
The anticipated benefits from public reporting of outcomes include enhanced transparency and 
accountability for hospitals which in turn enables patients to make informed choices about where they 
receive care.9 They should also  support quality improvement either through market mechanisms10 




Radiation oncology, is one of the major modalities of cancer control and cure, yet there is little or no 
evidence available that advances in practice are translating into better patient outcomes (survival, 
toxicity or function) across health care providers in the real world. Globally, there has been very 
limited public reporting of outcomes either of efficacy (e.g. local control, survival) or toxicity following 
radiotherapy and where they are available they almost exclusively consider structural or process 
indicators.13,14  
Benchmarking activities against process measures e.g. adherence to dosimetric criteria, use of image 
guided radiotherapy (IGRT)  and treatment margins have been undertaken using surveys and national 
quality improvement initiatives (e.g. Quality Research in Radiation Oncology).15-32 However, these 
measures remain quite limited in defining the quality of care received.33 This is due to a lack of a clearly 
defined link between process and outcome, as well as uncertainty regarding the magnitude of effect 
on functional and oncological outcomes from non-adherence.14,16 
In the United States , only the 11 cancer centres that are exempt from the prospective payment system 
are required to report performance indicators as part of the PPS-Exempt Cancer Hospital Quality 
Reporting Program (PCHQR)34. This is only a small fraction of the 3500 hospitals providing cancer 
services in the United States and none of these performance indicators relate to treatment outcomes 
(https://www.medicare.gov/hospitalcompare/cancer-measures-data.html). Groups in the 
Netherlands (https://www.iknl.nl/over-iknl/about-iknl; https://dica.nl/) and Canada 
(https://www.csqi.on.ca; https://www.systemperformance.ca) are developing outcome indicators 
but these initiatives remain a work in progress.8 The UK is the first country to introduce a national 
public outcomes reporting programme for radiotherapy.  
The NHS Cancer outcomes reporting programme  
In 2013, NHS England introduced the Clinical Outcomes Publication programme. This initiative set out 
to publish quality measures at the level of the individual consultant, team or hospital.35 The outcomes 
are expected to be provided by pre-existing national clinical audits as part of the National Clinical Audit 
and Patient Outcomes Programme.  The advantage of this in the context of the NHS is that it is a 
publicly-funded health care system covering 95% of patients receiving cancer treatment.  
There are currently five national cancer audits covering patients treated in the NHS in England and 
Wales2,36-39 – breast, bowel, oesophageal/gastric, prostate, and lung cancers. The National Prostate 
Cancer Audit (NPCA) 2 is unique in that it is the first of these audits to develop and measure  treatment-
outcome indicators for radical radiotherapy.  
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The National Prostate Cancer audit radiotherapy outcomes reporting programme 
Since 2019 the NPCA publishes risk-adjusted treatment toxicities and functional outcomes for each 
radiotherapy centre in England and Wales (n=55). One of the advantages of the NPCA approach is the 
use of pre-existing administrative datasets and hospital IT infrastructure, which minimises the burden 
of data collection on clinicians.  This includes four linked datasets (Hospital Episode Statistics (HES), 
cancer registry, the radiotherapy data set (RTDS), and the systemic anticancer treatment (SACT)), 
which provide information on patient and tumour characteristics, episodes of care and detailed 
information on radiotherapy treatment. The advantage of this approach is that it provides a 
standardised and validated mechanism for data capture with high levels of case ascertainment. This 
obviates increasing concerns regarding under-reporting of adverse events especially where care is 
fragmented across several hospitals, (e.g. centralised hub and spoke models). The second advantage 
is that it reduces the likelihood of misclassification bias by using a standardised coding approach, for 
grading toxicity which, is not dependent on individual clinician reporting. This improves specificity for 
the recording of outcomes.  
Another unique component of the NPCA is the survey collecting patient-reported outcome and 
experience measures on a large scale. These include the Expanded Prostate Cancer Index Composite 
short-form (EPIC-26), a validated instrument comprising 26 items to measure patient function and 
bother in five domains, and the EuroQol EQ-5D-5L, an instrument to measure health-related quality 
of life. The survey was sent out approximately 12 months after receipt of radical radiotherapy and has 
been also used to compare outcomes across different treatment practices.40 The first survey, 
published in 2018, had a 73% response rate (25,490 out of 35,162 questionnaires sent) and a second 
round of data collection will be published in 2020. Of the EPIC-26’s five main domains, two are selected 
routinely as part of the outcomes reporting programme.  
The reporting programme is designed to report outcomes, in order to identify both outlying 
performance and good practice as opposed to ranking individual centres. By using funnel plots to 
compare individual provider results with the national average, we identify ‘potential negative 
outliers’ whose performance is outside acceptable limits corresponding to three standard deviations 
(further from the national average than would usually occur by chance alone). 
https://www.npca.org.uk/resources/npca-outlier-policy/.41  
 
If outliers are identified, the hospital’s lead clinician, medical director and chief executive are 
contacted and given the opportunity to review their own data and provide a formal response 
including a local quality improvement plan that is published alongside the results for their hospital.2  
Patients, providers and commissioners are able to access the results for each NHS hospital providing 
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prostate cancer treatment services via the provider reporting portal on the audit website 
(https://www.npca.org.uk/provider-results/).  A Quality Improvement action plan template is also 
provided including the key recommendations from the report and suggested actions for providers. 
https://www.npca.org.uk/reports/npca-annual-report-2018/ . 
 
Development of the radiotherapy performance indicators 
The first indicator assesses the percentage of men at each radiotherapy centre who experienced at 
least one gastro-intestinal (GI) complication within 2 years of their radiotherapy (Figure 1), using 
procedure and diagnostic codes derived from patient-level linked administrative hospital data. A 
toxicity event requires evidence of both a diagnostic endoscopic procedure (e.g. colonoscopy or 
sigmoidoscopy) in addition to a diagnostic code consistent with radiation toxicity equivalent to Grade 
2 toxicity or above according to the National Cancer Institute Common Toxicity Criteria for Adverse 
Events (CTCAE).42,43 These indicators have been validated and used to compare the effectiveness of 
different treatment modalities and processes of care in prostate cancer radiotherapy.43-45  
For the hospital-level reporting programme, these toxicity indicators are adjusted for patient factors:  
age, cancer stage, comorbidities and socioeconomic status. However, they are not adjusted for 
treatment related factors (e.g. hypofractionation, pelvic lymph node treatment) because adjustment 
for differences in radiotherapy practice may inappropriately mask variation in outcomes between 
centres. Of note all NHS hospitals are delivering IMRT routinely and the audit does not report 
outcomes for patients receiving a brachytherapy boost or prostate bed radiotherapy.   
The second and third indicators report the mean bowel function and sexual function respectively for 
patients treated at each radiotherapy centre. The results are based on the national survey collection 
of patient-reported outcome and experience measures (PROMs/PREMs) (Figures 2 and 3). The sexual 
function domain asks questions related to the quality and frequency of erections. The bowel function 
domain assesses bowel frequency, urgency, bleeding and pain. These patient-reported outcome 
indicators are then linked with the administrative datasets described above to enable relevant risk-
adjustment prior to reporting.  
Outcome reporting – the experience to date 
The outcome reporting programme demonstrated considerable variation in toxicity across 
radiotherapy centres in the English and Welsh NHS. The overall rate of toxicity of Grade 2 or above is 
in the region of 10% at 2 years across all centres, but this varies by hospital ranging from 2% to 23% 
(Figure 1).  
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In the first year of the programme, two hospital ‘alarm’ outliers (whose rates of GI toxicity was more 
than three standard deviations from the national average) were identified as part of this process. 
Centres (both outliers and non-outliers) were able to request the audit data and review their 
outcomes and processes of care. This included case note review, analysis of dosimetry and 
radiotherapy contours, patient recall for assessment, and correspondence with primary care 
practitioners. These internal review processes validated the rates of toxicity reported through the 
audit. Only a very small number of patients had presented incidentally via the screening programme 
and the majority of referrals were for rectal bleeding. Formal responses from outliers are recorded in 
the audit reports.2  
The second and third indicators, which included centre-level EPIC-26 bowel and sexual function scores, 
also identified negative outliers (Figures 2 and 3). Despite different methods of determining GI adverse 
events, a correlation was demonstrated between negative outliers for GI toxicity on the basis of 
routine clinical data (first indicator) and GI dysfunction (second indicator) reported by patients.   
Three centres were identified as positive outliers because their results were below the lower 99.8% 
funnel limit for GI toxicity events (Figure 1). Of these three centres, one was also a positive outlier for 
bowel and sexual function scores from the patient reported outcomes and was consistently seen as 
the “best performer” when compared to all radiotherapy centres treating prostate cancer patients.  
Will outcome reporting improve treatment quality?  
The radiotherapy outcomes programme reported for the first time in 2019 and it is therefore too early 
to assess its impact on improvements in patient outcome: this will be tracked overtime by the NPCA. 
However, a number of initiatives have been set up in response to this programme.  
On a national level, an annual quality improvement workshop for all NHS radiotherapy treatment 
providers in England and Wales has been initiated. Here, radiotherapy centres have the opportunity 
to reflect on their own results, report findings from internal audits including correlating their 
outcomes with individual patient dosimetry data, as well as to learn from other centres. Box 1 
highlights factors identified from analysis of negative and positive outliers who provided insights into 
their practice and processes of care. In addition, examples of local quality improvement initiatives 
implemented since commencement of the outcomes programme are outlined in Box 2.  
Beyond prostate cancer, the impact of public reporting of hospital or clinician specific outcomes on 
the quality of patient care remains inconsistent at best.49,50 A study undertaken by the National Bowel 
Cancer Audit,51 found that the introduction of outcome reporting coincided with a reduction in 90-day 
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post-operative mortality from 2.8% to 2.1%, which exceeded the existing downward trend. 
Importantly, no risk-averse behaviour or gaming of data was observed.  
The mechanism by which improvements in outcome are achieved is unclear. In the wider literature, 
three pathways have been postulated. The “change” pathway hypothesises that public reporting and 
identifying low accomplishment provides a strong incentive for clinicians and providers to improve by 
appealing to their professionalism.52 On the other hand, the “selection” pathway puts patients at the 
heart of quality improvement by enabling them to choose better performing hospitals, which in turn 
motivates providers to improve quality to attract more patients and preserve or gain market share.53,54 
A third mechanism, “reputational loss,” appeals to the clinicians’ sense of their awareness of their 
standing among their colleagues. It has been suggested that this mechanism is a potential driver of 
quality improvement, particularly in poor-performing centres.55  
Will outcome reporting influence patient behaviour? 
The impact of outcome reporting on patient behaviour and patient selection of hospitals is a poorly 
researched area within cancer care.56 In other medical disciplines and health systems there is some 
evidence that patients move to seemingly better performing centres following publication of 
outcomes,57,58 but the results depend on the complexity of individual health systems and the nature 
and severity of the involved health conditions.  
With respect to prostate cancer, recent studies have demonstrated that prior to outcome reporting, 
1 in 3 patients undergoing  prostate cancer surgery and 1 in 5 receiving radical radiotherapy travel to 
a centre other than their nearest for treatment (termed patient mobility) in the English NHS.59-62 
Nearly all patients expressed an interest in having access to comparative outcome indicators to inform 
their choices.63 However, in their absence, factors such as the reputation of hospitals and individual 
clinicians, the availability of advanced technologies, and the experiences of other patients have been 
identified as most relevant.56,60,61  
It is important for the NPCA to avoid a common pitfall of public reporting, namely poor consumer or 
patient awareness of these indicators.5 The NPCA has sought to address this by engaging directly with 
patients and the public through its patient and public involvement (PPI) forum as well as its NHS clinical 
reference group which includes representation from national prostate cancer charities and support 
groups. These groups have been involved in the development of the clinical outcomes programme 
and through continued engagement with prostate cancer charities and support groups - who in turn 
are integrating this resource into their own information channels; it is expected that this information 
will inform decision-making. Empirically, we will assess this by analysing changes in patterns of patient 
mobility in response to outcome reporting using established methodologies.61 From the clinician 
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perspective we expect this centre-level information to help doctors and other health-care workers to 
counsel patients more effectively and transparently regarding toxicity and functional outcomes 
following radical treatment.  
 
Outcome reporting – Challenges and opportunities 
Infrastructure and political commitment 
The NPCA has demonstrated that it is feasible to develop outcome indicators for radiotherapy 
treatment and thereby produce a transparent mechanism for comparing the performance of 
providers.64,65 However, there are a number of challenges to creating a similar outcome reporting 
programme in other health systems.11 The differentiation of health care provision across private and 
public sectors makes the development of public reports that encompass all health-care provision a 
significant challenge.33 In addition, for many reporting programmes participation is optional and there 
is little uniformity across provider organisations in terms of the content of  public reports and the 
statistical and risk-adjustment methods.66,67 Attempts to create such centralised registries and 
national performance assessment projects in other countries have failed due to a lack of incentive 
amongst physicians and providers as well as the costs associated with collating data across heavily 
fragmented public and private systems.68 Other challenges, where registries exist, include poor 
completion of radiotherapy datasets (providing information on target volumes, dose, fractionation 
and site of treatment).16 
In the NHS, political commitment has ensured that the necessary financial resource has been made 
available to set up national cancer audits in England and Wales as part of the Clinical Outcomes 
Publication Programme. Methodological and clinical teams have been established who in turn have 
defined, developed and implemented performance indicators reflecting outcomes of cancer care at a 
national level. The cost itself for developing this programme, equates to approximately 1.7 million 
GBP over 5 years which is 0.002 % of the median estimated cost for developing a new therapeutic 
agent (710 million GBP)69 and is significant value for money given the information it provides around 
variation in  access and outcomes of cancer treatment.  
Gaming and inappropriate use of data 
The risk of “gaming”, where data may be manipulated to increase patients’ predicted risk or to make 
patients ineligible for public reporting, is likely to be negligible in the NPCA reporting programme as 
this uses existing administrative patient-level datasets and national surveys of patients using validated 
PROMs tools. The GI toxicity indicator also avoids the need for subjective assessment, addressing 
concerns that clinicians might manipulate outcome data.  In addition, clinicians and hospitals do not 
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select patients for the PROMS survey and they are blinded to the results. Instead, the survey is 
administered by an independent body, and sent to all patients treated at NHS hospitals. This also 
reduces the burden of data collection on hospitals. The high response rate (close to 75%) reflects the 
acceptance of patients for this process.  
Risk averse behaviour or “cream skimming”, whereby lower risk patients are differentially selected by 
clinicians for a procedure does remain a possibility with any reporting programme, but is minimised 
within the NPCA through hospital, rather than clinician level reporting, and the use of routine data for 
outcome assessment. To mitigate the impact of risk averse behaviour, the reporting system does 
adjust for age, stage, comorbidity and socioeconomic status. Other baseline factors may also be 
considered in the future. 
Indicator development - Efficacy and toxicity 
Developing outcome measures in cancer care is challenging as it is a complex discipline incorporating 
a diverse set of interventions delivered with radical or palliative intent, encapsulating modalities such 
as surgery, radiotherapy and chemotherapy either on their own or in combination.70 Generic outcome 
measures will rarely be applicable and will need to be adapted depending on the type of procedure 
and the cancer in question.  
For radiotherapy, the balance between efficacy e.g. local control and toxicity is essential to 
understanding outcome. However, some limitations exist to achieving this. For prostate cancer, it may 
be many years before it is appropriate to measure survival, during which time clinical practice can 
change considerably. As a result, treatment-related toxicity and patient-reported functional outcomes 
are of particular importance as they are available sooner and provide a meaningful measure of 
treatment effectiveness. This is particularly important in a specialty where  rapid technological change 
and iterations in practices  occur frequently.44,45  
As the radiotherapy outcomes programme extends towards other tumour types, measures of both 
toxicity and efficacy may be more readily achievable e.g in oesophageal cancer. However, this does 
require substantial methodological work as one of the limitations of these datasets is that they do not 
routinely record the date of key measures such as disease recurrence. Work is currently being 
undertaken across the audits to develop such measures e.g. disease free survival, and for prostate 
cancer specifically, this has involved the development of an indicator for skeletal related events.71 As 
reporting extends to other combination therapies, e.g. radiation followed by surgery for rectal cancer, 
a different profile of indicators may need to be considered which in addition to local control may need 
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to also include post-operative outcomes such as complication, readmission and permanent stoma 
rates.  
Value based health care and health care markets 
Currently there are significant differences in radiotherapy practice delivered nationally and 
internationally, both in terms of modalities and pathways of care (e.g. stereotactic versus intensity 
modulated radiotherapy/dose fractionation/IGRT) resulting in significant variation in costs, without a 
clear understanding of the impact of outcomes in the real world.72 
A major finding from the reporting programme is that the differences between the best and worst 
performers was not due to variation in access to innovation such as proton beam therapy (no NHS 
centres provide this treatment for prostate cancer) or rectal spacer techniques (only one NHS centre 
uses this routinely).  Instead, the national benchmarking exercise, described differences in quality 
assurance processes and routine practices (Box 1), which can be readily adopted immediately by all 
centres at negligible cost.  
Outcome reporting through greater transparency around best practices can therefore help to 
overcome this “information asymmetry” and reliance on proxies of healthcare quality (e.g. technology 
adoption, physician reputation), rationally guiding investments by purchasers of health services and 
limiting perverse incentives for hospitals to adopt inefficient practices of care.72  
Cancer surgery provides a relevant example of the potential negative impact of the absence of robust 
outcome data to inform choice. In the UK, patient choice and provider competition policies have 
influenced the widespread adoption of high-cost robotic technology for prostate surgery despite 
limited evidence that it improves -cancer-cure or functional outcomes.62,73 Information on treatment 
outcomes is therefore imperative to support patient choice, and the effectiveness of health care 
markets.   
In addition, in mixed public and private health care models the transparency and accountability that 
outcomes reporting brings within the public sector can form the basis for encouraging private health 
care providers to report their outcomes as part of a unified approach to outcome transparency and 
accountability74. This can be implemented through direct regulation or through patient’s voices, as 
consumers of health care demand information to guide their choices.  
Price transparency is another important issue and the quality outcomes reported can be linked with 
detailed pricing information. In systems such as the US, this approach could provide the necessary 
incentive to lower spending and improve care within managed health care markets.75,76,77  Conversely, 
in fixed priced markets such as the NHS, outcome reporting can also influence decisions of purchasers 
12 
or commissioners of health services with the aim of controlling costs or to obtain the best possible 
outcomes within a limited budget, particularly where reward or penalty schemes exist.78,79 More 
broadly within the radiotherapy arena, understanding these trade-offs would be greatly facilitated by 
standardising the methods for costing radiotherapy practices, which remain highly variable.80 In this 
regard, the Time Driven-Activity Based Costing model developed by the Health Economics in Radiation 
Oncology project, provides a framework for assessing the clinical and economic benefit of new 
radiation therapy technologies and supporting value based health care initiatives.7,81  
Conclusion 
The public reporting of patient outcomes at the individual hospital and clinician-level has been 
continuing apace since its initial introduction in the late 1980s. One of its major benefits is the 
enhanced transparency and accountability for hospitals regarding the quality of healthcare they 
deliver. In turn, these outcome indicators can enable patient choice, benchmark best practice and 
support quality improvement initiatives. This lack of public reporting in radiotherapy is largely due to 
limitations in data infrastructure, and fragmented health insurance schemes. The NHS in England and 
Wales has led the way for radiotherapy reporting since 2019, demonstrating the feasibility of collating 
and publishing outcomes at the hospital-level. The results are accessible to patients, the public and 
clinicians and are designed to identify outlying hospital performance and enable hospitals to 
benchmark their performance relative to the national average across all hospitals. The impact of the 
reporting programme needs further assessment and further work is ongoing to develop and refine 
new outcome indicators for prostate cancer and other tumour types. 
 
Search strategy and selection criteria: 
References for this review were identified through searches of PubMed with the search terms 
“Radiotherapy” AND (Patient Outcomes OR Clinical Outcomes”) AND (hospital OR provider) AND 
(“public reporting OR performance measurement OR rankings) from 01/01/1990 until 01/05/2020. 
Articles were also identified through searches of the authors’ own files. Only papers published in 
English were reviewed. The final reference list was generated on the basis of originality and relevance 
to the broad scope of this review. The search did not identify any evidence for other public 
radiotherapy outcomes reporting initiatives. Studies focused on local quality improvement initiatives 
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Figure 1 – Funnel plot demonstrating variation in rate of gastrointestinal toxicity across all NHS 
radiotherapy centres in England and Wales (n=55) 
 
Figure 2 – Funnel plot demonstrating variation in bowel function scores using EPIC-26 Patient 
Reported Outcome Measure across all NHS Radiotherapy Centres in England and Wales (n=55) 
Notes: 
1. Higher adjusted mean scores using EPIC-26 Patient Reported Outcome Measure are 
associated with better bowel function 
 
Figure 3 – Funnel plot demonstrating variation in sexual function scores using EPIC-26 Patient 
Reported Outcome Measure across all NHS Radiotherapy Centres in England and Wales (n=55) 
Notes: 
1. Higher adjusted mean scores using EPIC-26 Patient Reported Outcome Measure are 




BOX 1 – Findings from the internal review and audit undertaken by negative and positive outliers 
following publication of radiotherapy treatment outcomes 
 
Key considerations from negative outliers: 
• The indicators have picked up toxicities not identified in the centre’s internal audits. Reason: 
o A significant proportion of referrals are made in the community by primary care 
teams 
• Practices of care in line with recent trials (CHHiP study46), however significant heterogeneity 
in centre-level radiotherapy protocols exist when comparisons undertaken 
• Centres are using current standards in technology e.g. IMRT and IGRT (cone beam CT) 
• Variation in practice between clinicians observed in the same centre e.g. doses to target 
structures, margins, and treating volumes (e.g. inclusion of pelvic lymph nodes)  
• Physician peer review of contouring and dosimetry not routinely undertaken 
• Training issues and lack of experience amongst gastroenterology teams outside of specialist 
centres, may potentially “over-call” radiation toxicities   
Key considerations from positive outliers: 
• No new technology or technique in use over and above standard of care that is readily 
available across other NHS centres 
• Evolution of practice beyond trial protocols systematically undertaken to include: 
o Bowel protocols: diet plans and rectal enemas to minimise rectal volume 
o Contouring guidelines: Contemporary contouring guidelines for new trials integrated 
as standard of care across all patients e.g.PIVOTAL BOOST study 
o Treatment margins: Reduction in margins based on treatment set-up audit 
o Dosimetric constraints: Local adaptations to dosimetric constraints based on internal 
radiobiological modelling studies e.g. mean dose to rectum not to exceed 38Gy for 
patients receiving 60Gy in 20# 
o Image guidance: Use of fiducials routinely based on treatment set-up audit  





BOX 2 - Examples of Quality Improvement activities in response to public reporting of outcomes 
 
• Communication: Improved communication between staff members both within radiation 
oncology groups and across disciplines (radiation therapists, medical physicists, dosimetrists) 
• Quality improvement teams set up: Regular inter-disciplinary meetings set up to discuss 
nuances of practice including case selection, contouring, dosimetry and follow up processes.  
• Protocol and Institutional guidelines: Updates of local prostate cancer radiotherapy practice 
protocols e.g. dosimetry, margins, bowel preparation 
• Internal audit of outcomes:  
1. Audit of patients identified as having significant toxicity to assess entire process of 
treatment delivery to establish where improvements may be sought.  
2. Audit of treatment set-up and contouring to establish whether further reduction in 
margins are feasible and if fiducial markers should be considered 
• Peer review: Implementation of routine peer review processes for contours and plans 
• Dosimetry: Evolution of dosimetric guidelines – to tighter constraints guided by published 
research47  
• Target localisation: Evaluation of MRI guided planning  
• Image guidance: Programme initiated for fiducial marker insertion  
• New technologies: Consideration of peri-rectal spacers48 
• Linacs: Comparison of treatment set up and dosimetry between treatment machines in the 
e.g. Tomotherapy and VMAT to establish if differences exist 
• PROMs: PROMs programme set up within individual centres to collate outcomes 
prospectively for radiotherapy patients 
• Training: Improved training for staff members involved in patient assessment and follow up  
 
 
 
 
 
 
